Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

158.72

-1.54

(-0.96%)

At close: 04:00PM EDT

157.83

-0.89

(-0.56%)

After hours:

04:04PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Triple Moving Average Crossover

View all chart patterns

Performance Outlook

Previous Close	160.26
Open	160.74
Bid	157.70 x 900
Ask	159.76 x 800
Day's Range	158.50 - 161.61
52 Week Range	117.64 - 169.98
Volume	420,678
Avg. Volume	509,975

Market Cap	9.949B
Beta (5Y Monthly)	0.69
PE Ratio (TTM)	N/A
EPS (TTM)	-7.37
Earnings Date	Aug 03, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	201.89

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Jazz Pharmaceuticals plc
Analyst Report: Jazz Pharmaceuticals plcJazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Rating
Fair Value
Economic Moat
last monthMorningstar

All

Zacks
Wall Street Analysts Predict a 25% Upside in Jazz (JAZZ): Here's What You Should Know
The mean of analysts' price targets for Jazz (JAZZ) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Wall Street Analysts Believe SunOpta (STKL) Could Rally 25%: Here's is How to Trade
  Zacks
- Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 32%: Read This Before Placing a Bet
  Zacks
Zacks
JAZZ or CORT: Which Is the Better Value Stock Right Now?
JAZZ vs. CORT: Which Stock Is the Better Value Option?
Benzinga
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to $204 with a reiterated Buy rating on slightly increased forward EPS estimates. Jazz reported a thorough 2Q22 beat, with broad product outperformance vs. consensus across neuro and oncology, plus gross margin upside and light OPEX, HC Wainwright notes. As per the analyst, this looked to be Jazz’s second-biggest operating cash flow quarter ever, pushing net leverage down to 3.2x, six months ahead of the targeted